NCT06842407 Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
| NCT ID | NCT06842407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Checkmab S.r.l. |
| Condition | Healthy Donors |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-04-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2023-04-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.
Eligibility Criteria
Inclusion Criteria: * blood donors * age of 18 years or more * able to sign informed consent Exclusion Criteria: * age below 18 years * Positive for HIV, HCV, HBV * not suitable for blood donation * not able to understand or sign informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06842407 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Donors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06842407 currently recruiting?
Yes, NCT06842407 is actively recruiting participants. Contact the research team at renata.grifantini@checkmab.eu for enrollment information.
Where is the NCT06842407 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06842407 clinical trial?
NCT06842407 is sponsored by Checkmab S.r.l.. The trial plans to enroll 600 participants.